Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.68 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524256 | 0.88 | AHCY (0.67) | AHCYADORA2BDNMT1DNMT3BPDE8B | |
| SCHEMBL20191359 | 0.81 | AHCY (1.00) | AHCYADORA3ADORA2AADORA2B | |
| SCHEMBL21057423 | 0.79 | AHCY (0.71) | AHCYSLC28A1ADORA3ADORA2AADORA2B | |
| SCHEMBL9679135 | 0.78 | AHCY (0.80) | AHCYADORA3ADORA2AADORA2BDNMT1 | |
| SCHEMBL9470577 | 0.78 | AHCY (0.70) | AHCYSLC28A1ADORA2BSLC28A2 | |
| SCHEMBL10431839 | 0.77 | AHCY (0.65) | AHCYADORA3ADORA2A | |
| SCHEMBL12149496 | 0.77 | EGFR (0.43) | AHCYSLC28A1ADORA3ADORA2AADORA2B | |
| SCHEMBL3765564 | 0.77 | AHCY (0.58) | AHCYSLC28A1ADORA3ADORA2AADORA2B | |
| SCHEMBL368476 | 0.77 | AHCY (0.58) | AHCYSLC28A1ADORA3ADORA2AADORA2B | |
| SCHEMBL14635720 | 0.76 | AHCY (0.71) | AHCYADORA2BDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | AHCY 2407/4885SLC28A1 399/4885ADORA3 936/4885 |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | TYMP, PNP, NUDT1 | AHCY 1748/4885SLC28A1 53/4885ADORA3 167/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | AHCY 2407/4885SLC28A1 399/4885ADORA3 936/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | AHCY 2407/4885SLC28A1 399/4885ADORA3 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.